Journal Article

DKFZ-2020-01252

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Fatigue following radiotherapy of low-risk early breast cancer - a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419).

Forster, T. ; Jäkel, C.DKFZ* ; Akbaba, S. ; Krug, D. ; Krempien, R. ; Uhl, M. ; Häfner, M. F. ; König, L. ; Koerber, S. A. ; Harrabi, S. ; Bernhardt, D. ; Behnisch, R. ; Krisam, J. ; Hennigs, A. ; Sohn, C. ; Heil, J. ; Debus, J.DKFZ* ; Hörner-Rieber, J. (Last author)DKFZ*

2020
BioMed Central London

This record in other databases:  

Please use a persistent id in citations: doi:10.1186/s13014-020-01581-9

Abstract: Fatigue is one of the most common and distressing side-effects of breast cancer radiotherapy. According to current guidelines, accelerated partial breast irradiation (APBI) may be considered as an alternative treatment option for women with early-stage low-risk breast cancer. One method for APBI is single-dose intraoperative radiotherapy (IORT) applied directly to the tumor bed during breast conserving surgery (BCS). The COSMOPOLITAN trial therefore aims to analyze the intensity of fatigue following single-shot IORT with electrons (IOERT) compared to conventional hypofractionated whole breast irradiation (WBI) in low risk early breast cancer patients.This trial is conducted as a multicenter, prospective, randomized, two-arm phase II study comparing the intensity of fatigue in early-stage breast cancer (cT1cN0cM0, tumor size < 2,5 cm, ER pos. Her2neu neg., age > 50 years) treated either with WBI or APBI after BCS. Secondary outcomes investigated are tumor control, overall survival (OS), disease-free survival (DFS), acute and chronic toxicity, quality of life (QoL) and cosmesis. A total of 202 patients will be randomized into two arms: Patients in arm A will receive WBI (40.05 Gy, 15 fractions) after surgical resection, while patients in arm B will receive IOERT (21 Gy to the 90%-isodose) during BCS. Fatigue will be assessed 12 weeks post surgery with the help of the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale.The present trial aims to evaluate treatment response to compare single-shot intraoperative electron APBI to conventional WBI following BCS in early-stage low risk breast cancer patients. Fatigue is selected as the primary, patient-reported endpoint due its major clinical relevance.The study is prospectively registered on February 12th, 2019: Clinicaltrials.gov, NCT03838419. 'Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer (COSMOPOLITAN)'.Ongoing study. Start of recruitment was December 2019.

Note: #LA:E050#

---

Contributing Institute(s):

1. E050 KKE Strahlentherapie (E050)
2. DKTK HD zentral (HD01)

Research Program(s):

1. 315 - Imaging and radiooncology (POF3-315) (POF3-315)

Appears in the scientific report 2020

---

Database coverage:
; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---